2024
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).
Jayakrishnan R, Nassar A, Shepherd F, Lin J, Lin S, Shakya P, Dilling T, Bar J, Grohe C, Gupta S, Fitzgerald B, Adib E, Sankar K, Neal J, Yu H, Whitaker R, Velazquez Manana A, Naqash A, Goldberg S, Kim S. Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2024, 42: 8013-8013. DOI: 10.1200/jco.2024.42.16_suppl.8013.Peer-Reviewed Original ResearchALK+ non-small cell lung cancerALK tyrosine kinase inhibitorsNon-small cell lung cancerTreatment-related adverse eventsTyrosine kinase inhibitorsPD-L1 statusOverall survivalConcurrent chemoradiationPD-L1Retrospective studyTreatment discontinuation due to toxicityLocally-advanced non-small cell lung cancerDiscontinued due to toxicityMultivariate Cox regression modelEfficacy of alectinibInternational retrospective analysisOptimal consolidation therapyProgression-free survivalCell lung cancerCox regression modelsBaseline characteristics of ageStandard of careMedian OSStages of cancerConsolidation therapyRisk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy
Chakrani Z, Mellgard G, Saffran N, McCroskery S, Taylor N, Patel M, Liaw B, Galsky M, Oh W, Tsao C, Patel V. Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor–targeted Therapy. American Journal Of Clinical Oncology 2024, 47: 271-278. PMID: 38344754, DOI: 10.1097/coc.0000000000001087.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesReceptor-targeted therapyTreatment discontinuationSingle-institution retrospective review of patientsDiscontinued treatment due to toxicityTreatment discontinuation due to toxicityDiscontinued due to toxicityMultivariate analysisTreatment due to toxicityCastration-resistant prostate cancerSingle-institution retrospective reviewRetrospective review of patientsRisk of treatment discontinuationRisk factorsPatient-reported side effectsPatients discontinued treatmentTreatment-related toxicityEarly treatment discontinuationReview of patientsImprove survival outcomesDuration of treatmentLikelihood of treatment discontinuationProgression of diseaseTreatment toxicity
2020
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.
Arrillaga-Romany I, Kurz S, Tarapore R, Sumrall A, Butowski N, Harrison R, De Groot J, Chi A, Shonka N, Umemura Y, Odia Y, Mehta M, Nghiemphu P, Cloughesy T, Lu G, Oster W, Allen J, Batchelor T, Lassman A, Wen P. Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma. Journal Of Clinical Oncology 2020, 38: 3615-3615. DOI: 10.1200/jco.2020.38.15_suppl.3615.Peer-Reviewed Original ResearchH3 K27M-mutant diffuse midline gliomaBlinded independent central reviewPhase II clinical trialDiffuse midline gliomaII clinical trialsMidline gliomaTreatment discontinuation due to toxicityClinical trialsDiffuse midline glioma patientsDiscontinued due to toxicityH3 K27M-mutant gliomasNon-contrast-enhancing regionsGlioma patientsObjective response rateDuration of responseDopamine receptor expressionIndependent central reviewContrast-enhancing lesionsH3 K27MFirst-in-classT1 post-contrastAnti-cancer small moleculesStable diseaseData cutoffPrior radiationClinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.
Kawakibi A, Tarapore R, Gardner S, Kurz S, Wen P, Arrillaga-Romany I, Batchelor T, Butowski N, Sumrall A, Shonka N, Harrison R, De Groot J, Mehta M, Odia Y, Hall M, Cloughesy T, Ellingson B, Umemura Y, Allen J, Koschmann C. Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma. Journal Of Clinical Oncology 2020, 38: 3617-3617. DOI: 10.1200/jco.2020.38.15_suppl.3617.Peer-Reviewed Original ResearchH3 K27M-mutant gliomasNon-recurrent patientsGlioma patientsRecurrent patientsClinical efficacyTreatment discontinuation due to toxicityDiscontinued due to toxicityMedian duration of responseH3 K27M-mutantDose-limiting toxicityDuration of responseDiffuse midline gliomaExpression of DRD2Wild-type gliomasAntitumor responseMedian followMidline gliomaPrimary tumorRecurrent diseaseDRD2 expressionMedian durationDRD2 antagonistsMedian ageTumor DNAMedian time
2019
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.
Arrillaga I, Kurz S, Sumrall A, Butowski N, Harrison R, De Groot J, Shonka N, Lieberman F, Odia Y, Tarapore R, Merdinger K, Allen J, Oster W, Mehta M, Cloughesy T, Chi A, Lassman A, Batchelor T, Wen P. Single agent ONC201 in adult recurrent H3 K27M-mutant glioma. Journal Of Clinical Oncology 2019, 37: 3005-3005. DOI: 10.1200/jco.2019.37.15_suppl.3005.Peer-Reviewed Original ResearchH3 K27M-mutant gliomasResponse of stable diseaseStable diseaseMedian followTumor regressionTreatment discontinuation due to toxicitySingle agentDiscontinued due to toxicityMedian prior linesDose-limiting toxicityTreated with single agentsCompassionate use protocolProgression-FreePrior radiationPartial responseConfirmatory scanDRD2 antagonistsMedian ageAssociated with improvementsProgressive diseaseTumor lesionsOn-treatmentAdult patientsPoor prognosisNeurological symptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply